title: Nanotechnology: Deliver on a promise.
authors.forename: Jessica
authors.initials: J
authors.lastname: Wright
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000079963:Brentuximab Vedotin; D002166:Camptothecin / Q000008:administration & dosage; D003505:Cyclodextrins / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D016503:Drug Delivery Systems / Q000191:economics / Q000379:methods*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D008453:Maytansine / Q000008:administration & dosage / Q000031:analogs & derivatives; D058990:Molecular Targeted Therapy; D050997:Nanomedicine / Q000191:economics / Q000379:methods*; D053758:Nanoparticles / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D011092:Polyethylene Glycols / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003505:Cyclodextrins; C542292:IT-101; D018796:Immunoconjugates; C506643:liposomal doxorubicin; D008453:Maytansine; D011092:Polyethylene Glycols; D000079963:Brentuximab Vedotin; D004317:Doxorubicin; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine; D002166:Camptothecin